BUZZ-Enliven gains after Jones raises PT on increased takeover appeal

Reuters03-25
BUZZ-Enliven gains after Jones raises PT on increased takeover appeal

** Shares of drug developer Enliven Therapeutics ELVN.O rise 14.13% to $35.55 premarket

** Jones Trading raises PT to $45 from $35 and reiterates a "buy" rating

** Brokerage says Merck's MRK.N $6.7 billion deal to buy rival Terns Pharmaceuticals TERN.O means that both ELVN and TERN could "carve out their own market share" and increase ELVN's takeover appeal

** Both TERN and ELVN are developing drugs for chronic myeloid leukemia (CML), a cancer that starts in the bone marrow and causes uncontrolled growth of leukemia cells

** Brokerage says ELVN's lead drug, ELVN‑001, which has a different mechanism of action compared to Terns' drug, is best positioned for patients whose disease no longer responds to earlier treatments

** Says TERN's lead drug, TERN‑701, is expected to compete mainly in earlier treatment settings

** Adds ELVN is well positioned as a takeout target as most other CML drugs are owned by large drugmakers

** ELVN fell more than 31% in 2025

(Reporting by Kunal Das in Bengaluru)

((Kunal.Das2@thomsonreuters.com;))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment